がん組織診断の世界市場

Future Market Insightsが発行した調査報告書(FUMI709039)
◆英語タイトル:Cancer Tissue Diagnostics Market: North America to Retain Its Dominance Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016 - 2026
◆商品コード:FUMI709039
◆発行会社(リサーチ会社):Future Market Insights
◆発行日:2017年6月15日
◆ページ数:171
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Individual PriceUSD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
Corporate PriceUSD7,500 ⇒換算¥847,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Future Market Insights社の概要及び新刊レポートはこちらでご確認いただけます。

Future Market Insightsが発行した本調査レポートでは、がん組織診断の世界市場について調査・分析し、がん組織診断の世界市場動向、がん組織診断の世界市場規模、市場予測、セグメント別がん組織診断市場分析、地域別市場規模(北米市場、南米市場、アジア市場、日本市場、ヨーロッパ市場など)、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global cancer tissue diagnostics market is poised to grow from close to US$ 4,350 Mn in 2016 to nearly US$ 9,650 Mn by 2026 end. This represents a CAGR of 8.3% over the forecast period. The global market for cancer tissue diagnostics represents incremental opportunity of about US$ 5,300 Mn between 2016 and 2026.
Global Cancer Tissue Diagnostics Market Attractiveness Analysis by Region, 2016 – 2026

North America dominated the global cancer tissue diagnostics market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. North America accounted for 36.5% value share in 2016 and is projected to account for more than 40% share by 2026 end. In terms of value, APEJ is expected to register a CAGR of 8.0% during the forecast period. Despite a low value CAGR of 5.7%, the MEA cancer tissue diagnostics market is projected to grow 1.9X over 2016–2026.

Constantly growing list of cancer biomarkers boosting the cancer tissue diagnostics market

Sheer number of biomarkers that can be utilised for early cancer detection from blood or plasma samples are constantly increasing, which is expected to bring new cancer biomarker tests in the market in the near future. For instance, researchers at the University of Sheffield have recently identified over 700 new blood biomarkers that can be used for early cancer detection. As per OECD statistics, the global biomarkers market for companion diagnostics was valued at about US$ 8.4 Bn in 2016. The growth in companion diagnostics is indicative of acceptance of biomarkers in healthcare systems and may offer attractive incentives for biomarkers business development.

Advanced diagnostics at reduced costs aiding the global cancer tissue diagnostics market

After the completion of the human genome project in 2003, cost of assembling one genome has reduced tremendously and also cut down the time of analysis with development of highly advanced sequencing equipment. For instance, in January 2014, Illumina Inc. launched HighSeq X Ten Sequencer, which cut down the cost of genome sequencing to as low as US$ 1,000 including reagents cost and sample preparation equipment depreciation cost. Further advancements may continue to push down the cost for less than the cost of an X-ray, which would enhance the accessibility of this technology and thus drive the growth of the market. This also facilitates the use of highly advanced technologies by smaller research and clinical laboratories that possess less technical expertise and low resources.

Enormous R&D investment poses a threat to the expansion of the cancer tissue diagnostics market

Development of all high end instruments such as PET, MRI, SPECT equipment as well as next-generation sequencing platforms, analytical instruments used for laboratory analysis of cancer specimen etc. need huge investments of time and money, which is expected to be the prime factor impacting the cancer tissue diagnostics market. Also, all big pharmaceutical companies are entering into the diagnostics business and are thus cutting down the growth prospects of diagnostic giants such as Roche, Danaher etc. If at all a company develops innovative diagnostic testing, they still have to invest in expensive clinical utility studies, and there is no guarantee that the product will get coverage.

Meeting the needs of hospital laboratories presents a significant opportunity for the growth of the global cancer tissue diagnostics market

Due to healthcare cost containment in majority of mature markets, hospital based laboratories are facing pressure to supply more services at reduced costs. Healthcare facilities are facing increased aging population and rising prevalence of chronic diseases. By 2018, almost 10% of the global population will be 65 and above. Also global healthcare spending is expected to witness 5.2% growth every year till 2018. This imposes cost management pressure on diagnostic labs. Thus, several laboratories have started adapting informatics solutions, which helps them to increase overall productivity with existing resources. In line with this, manufacturers of diagnostic tests can grab the opportunity to provide complementary services and support. For instance, Abbott laboratories recently launched AlinIQ support and services to help their laboratory partners manage operations to maximise throughput and capacity.

【レポートの目次】

Table Of Content

1. Executive Summary

2. Cancer Tissue Diagnostics Introduction

2.1. Cancer Tissue Diagnostics Definition

2.2. Cancer Tissue Diagnostics Taxonomy

3. Cancer Tissue Diagnostics Analysis Scenario

3.1. Cancer Tissue Diagnostics Size (US$ Mn) and Forecast

3.1.1. Market Size and Y-o-Y Growth

3.1.2. Absolute $ Opportunity

4. Cancer Tissue Diagnostics Analysis Scenario

4.1. Macro-economic Factors

4.2. Drivers

4.2.1. Supply Side

4.2.2. Demand Side

4.3. Restraints

4.4. Opportunity

4.5. Trends

4.6. Cancer Epidemiology

4.7. Cancer Tissue Diagnostics Regulatory and Reimbursement Scenario

4.8. Porter’s Analysis

5. Global Cancer Tissue Diagnostics Analysis and Forecast, By Test Type

5.1. Introduction

5.1.1. Basis Point Share (BPS) Analysis By Test Type

5.1.2. Y-o-Y Growth Projections By Test Type

5.2. Market Size (US$ Mn) Forecast By Test Type

5.2.1. Immunohistochemical (IHC) Test

5.2.1.1. Breast Cancer

5.2.1.2. Stomach (gastric) Cancer

5.2.1.3. Colorectal Cancer

5.2.1.4. Prostate Cancer

5.2.1.5. Others

5.2.2. In situ hybridization (ISH) Test

5.2.2.1. Breast Cancer

5.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

5.2.2.3. Bladder Cancer

5.2.2.4. Others

5.3. Market Attractiveness Analysis By Test Type

6. Global Cancer Tissue Diagnostics Analysis and Forecast, By Region

6.1. Introduction

6.1.1. Basis Point Share (BPS) Analysis By Region

6.1.2. Y-o-Y Growth Projections By Region

6.2. Market Size (US$ Mn) Forecast By Region

6.2.1. North America

6.2.2. Western Europe

6.2.3. Asia Pacific Excl. Japan (APEJ)

6.2.4. Japan

6.2.5. Latin America

6.2.6. Eastern Europe

6.2.7. Middle East and Africa (MEA)

6.3. Market Attractiveness Analysis By Region

7. North America Cancer Tissue Diagnostics Analysis and Forecast

7.1. Introduction

7.1.1. Basis Point Share (BPS) Analysis

7.1.2. Y-o-Y Growth Projections

7.2. Market Size (US$ Mn) Forecast By Test Type

7.2.1. Immunohistochemical (IHC) Test

7.2.1.1. Breast Cancer

7.2.1.2. Stomach (gastric) Cancer

7.2.1.3. Colorectal Cancer

7.2.1.4. Prostate Cancer

7.2.1.5. Others

7.2.2. In situ hybridization (ISH) Test

7.2.2.1. Breast Cancer

7.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

7.2.2.3. Bladder Cancer

7.2.2.4. Others

7.3. Market Value Forecast By Country, 2016–2026

7.3.1. United States

7.3.2. Canada

7.4. Market Attractiveness Analysis

7.4.1. By Test Type

7.4.2. By Country

8. Latin America Cancer Tissue Diagnostics Analysis and Forecast

8.1. Introduction

8.1.1. Basis Point Share (BPS) Analysis

8.1.2. Y-o-Y Growth Projections

8.2. Market Size (US$ Mn) Forecast By Test Type

8.2.1. Immunohistochemical (IHC) Test

8.2.1.1. Breast Cancer

8.2.1.2. Stomach (gastric) Cancer

8.2.1.3. Colorectal Cancer

8.2.1.4. Prostate Cancer

8.2.1.5. Others

8.2.2. In situ hybridization (ISH) Test

8.2.2.1. Breast Cancer

8.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

8.2.2.3. Bladder Cancer

8.2.2.4. Others

8.3. Market Value Forecast By Country, 2016–2026

8.3.1. Brazil

8.3.2. Mexico

8.3.3. Rest of Latin America

8.4. Market Attractiveness Analysis

8.4.1. By Test Type

8.4.2. By Country

9. Western Europe Cancer Tissue Diagnostics Analysis and Forecast

9.1. Introduction

9.1.1. Basis Point Share (BPS) Analysis

9.1.2. Y-o-Y Growth Projections

9.2. Market Size (US$ Mn) Forecast By Test Type

9.2.1. Immunohistochemical (IHC) Test

9.2.1.1. Breast Cancer

9.2.1.2. Stomach (gastric) Cancer

9.2.1.3. Colorectal Cancer

9.2.1.4. Prostate Cancer

9.2.1.5. Others

9.2.2. In situ hybridization (ISH) Test

9.2.2.1. Breast Cancer

9.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

9.2.2.3. Bladder Cancer

9.2.2.4. Others

9.3. Market Value Forecast By Country, 2016–2026

9.3.1. UK

9.3.2. France

9.3.3. Germany

9.3.4. Spain

9.3.5. Italy

9.3.6. Rest of Western Europe

9.4. Market Attractiveness Analysis

9.4.1. By Test Type

9.4.2. By Country

10. Eastern Europe Cancer Tissue Diagnostics Analysis and Forecast

10.1. Introduction

10.1.1. Basis Point Share (BPS) Analysis

10.1.2. Y-o-Y Growth Projections

10.2. Market Size (US$ Mn) Forecast By Test Type

10.2.1. Immunohistochemical (IHC) Test

10.2.1.1. Breast Cancer

10.2.1.2. Stomach (gastric) Cancer

10.2.1.3. Colorectal Cancer

10.2.1.4. Prostate Cancer

10.2.1.5. Others

10.2.2. In situ hybridization (ISH) Test

10.2.2.1. Breast Cancer

10.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

10.2.2.3. Bladder Cancer

10.2.2.4. Others

10.3. Market Value Forecast By Country, 2016–2026

10.3.1. Russia

10.3.2. Poland

10.3.3. Rest of Eastern Europe

10.4. Market Attractiveness Analysis

10.4.1. By Test Type

10.4.2. By Country

11. Asia Pacific Excl. Japan (APEJ) Cancer Tissue Diagnostics Analysis and Forecast

11.1. Introduction

11.1.1. Basis Point Share (BPS) Analysis

11.1.2. Y-o-Y Growth Projections

11.2. Market Size (US$ Mn) Forecast By Test Type

11.2.1. Immunohistochemical (IHC) Test

11.2.1.1. Breast Cancer

11.2.1.2. Stomach (gastric) Cancer

11.2.1.3. Colorectal Cancer

11.2.1.4. Prostate Cancer

11.2.1.5. Others

11.2.2. In situ hybridization (ISH) Test

11.2.2.1. Breast Cancer

11.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

11.2.2.3. Bladder Cancer

11.2.2.4. Others

11.3. Market Value Forecast By Country, 2016–2026

11.3.1. China

11.3.2. Australia

11.3.3. India

11.3.4. ASEAN

11.3.5. Rest of APEJ

11.4. Market Attractiveness Analysis

11.4.1. By Test Type

11.4.2. By Country

12. Japan Cancer Tissue Diagnostics Analysis and Forecast

12.1. Introduction

12.1.1. Basis Point Share (BPS) Analysis

12.1.2. Y-o-Y Growth Projections

12.2. Market Size (US$ Mn) Forecast By Test Type

12.2.1. Immunohistochemical (IHC) Test

12.2.1.1. Breast Cancer

12.2.1.2. Stomach (gastric) Cancer

12.2.1.3. Colorectal Cancer

12.2.1.4. Prostate Cancer

12.2.1.5. Others

12.2.2. In situ hybridization (ISH) Test

12.2.2.1. Breast Cancer

12.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

12.2.2.3. Bladder Cancer

12.2.2.4. Others

12.3. Market Attractiveness Analysis

12.3.1. By Test Type

13. MEA Cancer Tissue Diagnostics Analysis and Forecast

13.1. Introduction

13.1.1. Basis Point Share (BPS) Analysis

13.1.2. Y-o-Y Growth Projections

13.2. Market Size (US$ Mn) Forecast By Test Type

13.2.1. Immunohistochemical (IHC) Test

13.2.1.1. Breast Cancer

13.2.1.2. Stomach (gastric) Cancer

13.2.1.3. Colorectal Cancer

13.2.1.4. Prostate Cancer

13.2.1.5. Others

13.2.2. In situ hybridization (ISH) Test

13.2.2.1. Breast Cancer

13.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

13.2.2.3. Bladder Cancer

13.2.2.4. Others

13.3. Market Value Forecast By Country, 2016–2026

13.3.1. GCC Countries

13.3.2. South Africa

13.3.3. Rest of MEA

13.4. Market Attractiveness Analysis

13.4.1. By Test Type

13.4.2. By Country

14. Competition Landscape

14.1. Competition Dashboard

14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

14.2.1. Abbott Laboratories

14.2.2. F. Hoffmann-La Roche Ltd.

14.2.3. Thermo Fisher Scientific Inc.

14.2.4. Ventana Medical Systems, Inc

14.2.5. Bio Rad Laboratories Inc.

14.2.6. Enzo Life Sciences, Inc.

14.2.7. Abcam plc.

14.2.8. BioGenex

14.2.9. Cell Signaling Technology, Inc.

14.2.10. Agilent Technologies, Inc.

14.2.11. PerkinElmer Inc.

14.2.12. Bio SB

14.2.13. Cancer Genetics Inc.

14.2.14. Danaher Corporation

14.2.15. ROSETTA GENOMICS

14.2.16. Nanoprobes, Inc.,

14.2.17. Creative-Biolabs

14.2.18. Enzo Life Sciences, Inc

14.2.19.Sigma-Aldrich Co. LLC

15. Assumptions and Acronyms Used

16.Research Methodology
List of Tables

Table 1: Global Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 2: Global Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Region, 2015 – 2026

Table 3: North America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 4: North America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 5: Latin America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 6: Latin America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 7: Western Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 8: Western Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

The market is expected to sTable revenue growth over the forecast period fuelled by demand for breast & lung cancer detection

Table 9: Eastern Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 10: Eastern Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 11: APEJ Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 12: APEJ Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Regional market revenue growth for both tests is expected to remain sTable over the forecast period, given rising demand

Table 13: Japan Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 14: MEA Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 15: MEA Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026
List of Figures

Figure 1 : Global Cancer Tissue Diagnostics Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 2 : Global Cancer Tissue Diagnostics Market Absolute $ Opportunity, 2016–2026

Figure 3: Global Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 4: Global Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026

Figure 5: Global Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 6: Global Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026

Figure 7: Global Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026

Figure 8: Global Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026

Figure 9: Global Cancer Tissue Diagnostics Market Share Analysis (%) By Region, 2016 & 2026

Figure 10: Global Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Region, 2015–2026

Figure 11: North America Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 12: Latin America Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 13: Western Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 14: Eastern Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 15: APEJ Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 16: Japan Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 17: MEA Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 18: Global Cancer Tissue Diagnostics Market Attractiveness Analysis By Region, 2016–2026

Figure 19: North America Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016, 2026

Figure 20: North America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 21: North America Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 22: North America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026

Figure 23: North America Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 24: North America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026

Figure 25: U.S. Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 26: Canada Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 27: North America Cancer Tissue Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026

Figure 28: North America Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026

Figure 29: North America Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026

Figure 30: Latin America Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

Figure 31: Latin America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 32: Latin America Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 33: Latin America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026

Figure 34: Latin America Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 35: Latin America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026

Figure 36: Brazil Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 37: Mexico Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 38: Rest of Latin America Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 39: Latin America Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

Figure 40: Latin America Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026

Figure 41: Latin America Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026

Figure 42: Western Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

Figure 43: Western Europe Cancer Tissue Diagnostics Market

Figure 44: Western Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 45: Western Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026

Figure 46: Western Europe Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 47: Western Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026

Figure 48: Germany Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 49: Italy Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 50: France Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 51: U.K. Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 52: Spain Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 53: Rest Of Western Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 54: Western Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

Figure 55: Western Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026

Figure 56: Western Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026

Figure 57: Eastern Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

Figure 58: Eastern Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 59: Eastern Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 60: Eastern Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026

Figure 61: Eastern Europe Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 62: Eastern Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026

Figure 63: Poland Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 64: Russia Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 65: Rest of Eastern Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 66: Eastern Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

Figure 67: Eastern Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026

Figure 68: Eastern Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026

Figure 69: APEJ Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

Figure 70: APEJ Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 71: APEJ Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 72: APEJ Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026

Figure 73: APEJ Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 74: APEJ Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026

Figure 75: China Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 76: India Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 77: ASEAN Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 78: Australia Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 79: Rest of APEJ Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 80: APEJ Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

Figure 81: APEJ Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026

Figure 82: APEJ Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026

Figure 83: Japan Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 84: Japan Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026

Figure 85: Japan Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 86: Japan Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026

Figure 87: Japan Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026

Figure 88: Japan Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026

Figure 89: MEA Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016, 2026

Figure 90: MEA Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026

Figure 91: MEA Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 92: Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026

Figure 93: MEA Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 94: MEA Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026

Figure 95: GCC Countries Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 96: South Africa Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 97: Rest of MEA Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 98: MEA Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026

Figure 99: MEA Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026

Figure 100: MEA Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026
Need more information about this report ?

Key Benefits

DIRECT ACCESS TO ANALYST

Get you queries resolved from our expert analysts before and after purchasing the report
CUSTOMIZE AS PER RESEARCH REQUIREMENT

Our expert team will assist and customize the report so that it best fit your exact requirement
INIMITABLE EXPERTISE ABOUT NICHE & EMERGING MARKETS

In-depth knowledge about emerging technologies across markets
ASSURED QUALITY

Enhanced focus on the quality and accuracy of the report

Call us on : + 44 (0) 20 7692 8790
OR

Select license type

Individual Price : $ 5000.00 Corporate Price : $ 7500.00 Enterprise Price : $ 10,000.00

Related Reports

Surgical Stapling Devices Market: APEJ, Western Europe, & North America in a Cutthroat Competition to Record the Highest CAGR Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016-2026
Muscle Stimulation Devices Market: Increasing Consumer Inclination towards Fitness & Sports, Coupled with High adoption in Physiotherapy Clinics & Home Care Settings to Boost Demand: Global Industry Analysis and Opportunity Assessment, 2016 – 2026
Endovenous Laser Therapy Market: Increasing Adoption of Endovenous Laser Therapy for Varicose Veins Treatment Likely to Fuel Market Revenue Growth: Global Industry Analysis and Opportunity Assessment 2016-2026
Global Pharmacovigilance Market: Increased regulatory convergence and stringent reporting measures to define pharmacovigilance activities globally
Static Compression Therapy Market : High incidence of Diabetes and Venous Ulcer to drive the demand for Static Compression Therapy Products : India Industry Analysis and Opportunity Assessment, 2015 – 2025



【レポートのキーワード】

がん組織診断

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ がん組織診断の世界市場(Cancer Tissue Diagnostics Market: North America to Retain Its Dominance Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016 - 2026)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆